National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies Date
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 7 of 7 Research Studies DisplayedBasu A, Sohn MW, Bartle B
Development and validation of the real-world progression in diabetes (RAPIDS) model.
This study investigated the value of using the real-world progression in diabetes (RAPIDS) model to increase medication inherence among Veterans Administration (VA) patients. Over 500,000 patients were tracked in 2003 with a 9-year followup. The model includes predictions as to outcomes and medication adherence and was found to be effective.
AHRQ-funded; HS018542.
Citation: Basu A, Sohn MW, Bartle B .
Development and validation of the real-world progression in diabetes (RAPIDS) model.
Med Decis Making 2019 Feb;39(2):137-51. doi: 10.1177/0272989x18817521..
Keywords: Comparative Effectiveness, Diabetes, Medication
Maruther NM, Tseng E, Huftless S
Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: A systematic review and meta-analysis.
The purpose of this study was to evaluate the comparative effectiveness and safety of monotherapy and selected metformin-based combinations in adults with type 2 diabetes. It found that the evidence supports metformin as first-line therapy for type 2 diabetes, given its relative safety and beneficial effects on hemoglobin A1c, weight, and cardiovascular mortality (compared with sulfonylureas). AHRQ-funded; 290-201-200007.
AHRQ-funded; 290201200007I.
Citation: Maruther NM, Tseng E, Huftless S .
Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: A systematic review and meta-analysis.
Ann Intern Med 2016 Jun 7;164(11):740-51. doi: 10.7326/m15-2650.
.
.
Keywords: Comparative Effectiveness, Medication, Diabetes, Evidence-Based Practice, Medication: Safety
Ferrara A, Hedderson MM, Brown SD
The comparative effectiveness of diabetes prevention strategies to reduce postpartum weight retention in women with gestational diabetes mellitus: the gestational diabetes' effects on moms (GEM) cluster randomized controlled trial.
The researchers compared the effectiveness of diabetes prevention strategies addressing postpartum weight retention for women with gestational diabetes mellitus (GDM) delivered at the health system level: mailed recommendations (usual care) versus usual care plus a Diabetes Prevention Program (DPP)-derived lifestyle intervention. They found that a DPP-derived lifestyle intervention modestly reduced postpartum weight retention and increased vigorous-intensity physical activity.
AHRQ-funded; HS019367.
Citation: Ferrara A, Hedderson MM, Brown SD .
The comparative effectiveness of diabetes prevention strategies to reduce postpartum weight retention in women with gestational diabetes mellitus: the gestational diabetes' effects on moms (GEM) cluster randomized controlled trial.
Diabetes Care 2016 Jan;39(1):65-74. doi: 10.2337/dc15-1254.
.
.
Keywords: Comparative Effectiveness, Diabetes, Lifestyle Changes, Pregnancy, Prevention, Women
Prentice JC, Conlin PR, Gellad WF
Capitalizing on prescribing pattern variation to compare medications for type 2 diabetes.
This study used observational quasi-experimental methods using instrumental variables (IVs) to compare the effect of two hypoglycemic medications, sulfonylureas (SUs) and thiazolidinediones (TZDs), on long-term outcomes. It found that individuals who used an SU as a second-line agent experienced significantly more adverse long-term health outcomes than did individuals who started on a TZD.
AHRQ-funded; HS019708.
Citation: Prentice JC, Conlin PR, Gellad WF .
Capitalizing on prescribing pattern variation to compare medications for type 2 diabetes.
Value Health 2014 Dec;17(8):854-62. doi: 10.1016/j.jval.2014.08.2674..
Keywords: Diabetes, Medication, Outcomes, Comparative Effectiveness
Zhang Y, McCoy RG, Mason JE
Second-line agents for glycemic control for type 2 diabetes: are newer agents better?
The researchers aimed to assess the benefits and harms of four commonly used antihyperglycemia treatment regimens considering clinical effectiveness, quality of life, and cost. According to the model used by the researchers, all regimens resulted in similar life years and quality-adjusted life years (QALYs) regardless of glycemic control goal, but the regimen with sulfonylurea incurred significantly lower cost per QALY.
AHRQ-funded; HS017628.
Citation: Zhang Y, McCoy RG, Mason JE .
Second-line agents for glycemic control for type 2 diabetes: are newer agents better?
Diabetes Care 2014;37(5):1338-45. doi: 10.2337/dc13-1901..
Keywords: Diabetes, Comparative Effectiveness, Quality of Life, Medication
Neugebauer R, Fireman B, Roy JA
Impact of specific glucose-control strategies on microvascular and macrovascular outcomes in 58,000 adults with type 2 diabetes.
This study used comparative effectiveness research methods to compare the effect of four distinct glucose-control strategies on subsequent myocardial infarction and nephropathy in type 2 diabetes. It found that in a large group of adults with type 2 diabetes, more aggressive glucose-control strategies have mixed short-term effects on microvascular complications and do not reduce the myocardial infarction rate over 4 years of follow-up.
AHRQ-funded; 29020050033I.
Citation: Neugebauer R, Fireman B, Roy JA .
Impact of specific glucose-control strategies on microvascular and macrovascular outcomes in 58,000 adults with type 2 diabetes.
Diabetes Care 2013 Nov;36(11):3510-6. doi: 10.2337/dc12-2675..
Keywords: Comparative Effectiveness, Diabetes, Outcomes, Patient-Centered Outcomes Research, Treatments
Raebel MA, Xu S, Goodrich GK
Initial antihyperglycemic drug therapy among 241 327 adults with newly identified diabetes from 2005 through 2010: a surveillance, prevention, and management of diabetes mellitus (SUPREME-DM) study.
This study sought to identify predictors of initiating any antihyperglycemic medication, and specifically sulfonylurea versus metformin in patients with newly diagnosed with diabetes. Most (59.7 percent) patients with newly diagnosed diabetes did not start any antihyperglycemic medication. Among those who did, metformin was generally the first antihyperglycemic initiated.
AHRQ-funded; HS019859
Citation: Raebel MA, Xu S, Goodrich GK .
Initial antihyperglycemic drug therapy among 241 327 adults with newly identified diabetes from 2005 through 2010: a surveillance, prevention, and management of diabetes mellitus (SUPREME-DM) study.
Ann Pharmacother. 2013 Oct;47(10):1280-91. doi: 10.1177/1060028013503624..
Keywords: Diabetes, Medication, Comparative Effectiveness